 | • レポートコード：QYR9ST14548 • 出版社/出版日：QYResearch / 2019年9月10日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療・製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| ※当調査レポートでは、皮膚線維症の治療の世界市場について調査・分析し、皮膚線維症の治療の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（免疫療法、コルチコステロイド、抗線維化薬、免疫グロブリン）、用途別（病院薬局、小売薬局、オンライン薬局）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の皮膚線維症の治療市場動向 ・主要企業別マーケットシェア ・皮膚線維症の治療の種類別市場規模2014-2019 （免疫療法、コルチコステロイド、抗線維化薬、免疫グロブリン） ・皮膚線維症の治療の用途別市場規模2014-2019 （病院薬局、小売薬局、オンライン薬局） ・皮膚線維症の治療の北米市場：主要企業・種類別/用途別市場規模 ・皮膚線維症の治療のヨーロッパ市場：主要企業・種類別/用途別市場規模 ・皮膚線維症の治療の中国市場：主要企業・種類別/用途別市場規模 ・皮膚線維症の治療の日本国内市場：主要企業・種類別/用途別市場規模 ・皮膚線維症の治療の東南アジア市場：主要企業・種類別/用途別市場規模 ・皮膚線維症の治療のインド市場：主要企業・種類別/用途別市場規模 ・皮膚線維症の治療の中南米市場：主要企業・種類別/用途別市場規模 ・主要企業のプロフィール （AbbVie、Bayer、Merck、Bristol-Myers Squibb、Sanofi、Boehringer Ingelheim、Roche、GlaxoSmithKline、Pfizer、Novartis、LEO Pharma、Actelion） ・皮膚線維症の治療の市場規模予測2019-2025 （種類別、用途別、地域別市場予測） ・アナリストの観点・結論 ... |
Cutaneous fibrosis is the accumulation of extracellular matrix (ECM) components in the dermis, leading to compromised function and altered architecture of the dermis. Development of fibrosis occurs naturally during scar formation in wound repair or is a pathological process in pro-fibrotic diseases.
Cutaneous fibrosis is a fundamental feature of fatty skin sclerosis and is associated with increased levels of the cytokine transforming growth factor-β,186. This growth factor may be derived from activated leukocytes, recruit’s macrophages and fibroblasts into the tissue and leads to the production of extracellular matrix proteins by dermal fibroblasts. The goal of skin fibrosis treatment is the restore abnormally activated dermal fibroblasts producing the excessive amount of extracellular matrix, which is generally a final consequence of the complex disease process including the activation of vascular and immune systems.
The prototype of fibrotic skin disease is scleroderma, which can be divided into whole body and local forms. Progressive systemic sclerosis (PSS) is a widespread connective tissue disease in which the fibrotic process affects not only the skin but also the lungs, heart, kidneys and gastrointestinal tract.
The classification of Cutaneous Fibrosis Treatment includes Immunotherapy, Corticosteroids, Anti-Fibrotic Drugs and Immunoglobulins. And the proportion of Immunotherapy in 2018 is about 48.94%. Cutaneous Fibrosis Treatment is widely in Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies. The proportion of Hospitals Pharmacies in 2018 is about 54.74%.Europe is the largest consumption place, with a consumption market share nearly 32.17% in 2018. Following Europe, North America is the second largest consumption place with the consumption market share of 30.35%. Market competition is intense. AbbVie, Bayer, Merck, Bristol-Myers Squibb, Sanofi, Boehringer Ingelheim, Roche, GlaxoSmithKline, Pfizer, Novartis, LEO Pharma, Actelion. are the leaders of the industry. Regional players in the cutaneous fibrosis treatment market also hold significant share which makes the cutaneous fibrosis treatment market highly fragmented.
In 2018, the global Cutaneous Fibrosis Treatment market size was 475.1 million US$ and it is expected to reach 723.7 million US$ by the end of 2025, with a CAGR of 6.2% during 2019-2025.
This report focuses on the global Cutaneous Fibrosis Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cutaneous Fibrosis Treatment development in North America and Europe..
The key players covered in this study
AbbVie
Bayer
Merck
Bristol-Myers Squibb
Sanofi
Boehringer Ingelheim
Roche
GlaxoSmithKline
Pfizer
Novartis
LEO Pharma
Actelion
Market segment by Type, the product can be split into
Immunotherapy
Corticosteroids
Anti-Fibrotic Drugs
Immunoglobulins
In 2018, Immunotherapy accounted for a major share of 49% the global Cutaneous Fibrosis Treatment market. And this product segment is poised to reach 340 million US$ by 2025 from 232.5 million US$ in 2018.
Market segment by Application, split into
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
In Cutaneous Fibrosis Treatment market, the Hospitals Pharmacies holds an important share in terms of application, and it is expected to reach a revenue of 385.25 by 2025, at a CAGR of 5.71% during 2019 and 2025.
Market segment by Regions/Countries, this report covers
North America
Europe
The study objectives of this report are:
To analyze global Cutaneous Fibrosis Treatment status, future forecast, growth opportunity, key market and key players.
To present the Cutaneous Fibrosis Treatment development in North America and Europe..
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Cutaneous Fibrosis Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Cutaneous Fibrosis Treatment Market Size Growth Rate by Type (2014-2025)
1.4.2 Immunotherapy
1.4.3 Corticosteroids
1.4.4 Anti-Fibrotic Drugs
1.4.5 Immunoglobulins
1.5 Market by Application
1.5.1 Global Cutaneous Fibrosis Treatment Market Share by Application (2019-2025)
1.5.2 Hospitals Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Cutaneous Fibrosis Treatment Market Size
2.2 Cutaneous Fibrosis Treatment Growth Trends by Regions
2.2.1 Cutaneous Fibrosis Treatment Market Size by Regions (2019-2025)
2.2.2 Cutaneous Fibrosis Treatment Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
3 Market Share by Key Players
3.1 Cutaneous Fibrosis Treatment Market Size by by Players
3.1.1 Global Cutaneous Fibrosis Treatment Revenue by by Players (2014-2019)
3.1.2 Global Cutaneous Fibrosis Treatment Revenue Market Share by by Players (2014-2019)
3.1.3 Global Cutaneous Fibrosis Treatment Market Concentration Ratio (CR5 and HHI)
3.2 Cutaneous Fibrosis Treatment Key Players Head office and Area Served
3.3 Key Players Cutaneous Fibrosis Treatment Product/Solution/Service
3.4 Date of Enter into Cutaneous Fibrosis Treatment Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
4.1 Global Cutaneous Fibrosis Treatment Market Size by Type (2014-2019)
4.2 Global Cutaneous Fibrosis Treatment Market Size by Application (2014-2019)
5 North America
5.1 North America Cutaneous Fibrosis Treatment Market Size (2014-2019)
5.2 Cutaneous Fibrosis Treatment Key Players in North America
5.3 North America Cutaneous Fibrosis Treatment Market Size by Type
5.4 North America Cutaneous Fibrosis Treatment Market Size by Application
6 Europe
6.1 Europe Cutaneous Fibrosis Treatment Market Size (2014-2019)
6.2 Cutaneous Fibrosis Treatment Key Players in Europe
6.3 Europe Cutaneous Fibrosis Treatment Market Size by Type
6.4 Europe Cutaneous Fibrosis Treatment Market Size by Application
7 International Players Profiles
7.1 AbbVie
7.1.1 AbbVie Company Details
7.1.2 Company Description and Business Overview
7.1.3 Cutaneous Fibrosis Treatment Introduction
7.1.4 AbbVie Revenue in Cutaneous Fibrosis Treatment Business (2014-2019))
7.1.5 AbbVie Recent Development
7.2 Bayer
7.2.1 Bayer Company Details
7.2.2 Company Description and Business Overview
7.2.3 Cutaneous Fibrosis Treatment Introduction
7.2.4 Bayer Revenue in Cutaneous Fibrosis Treatment Business (2014-2019)
7.2.5 Bayer Recent Development
7.3 Merck
7.3.1 Merck Company Details
7.3.2 Company Description and Business Overview
7.3.3 Cutaneous Fibrosis Treatment Introduction
7.3.4 Merck Revenue in Cutaneous Fibrosis Treatment Business (2014-2019)
7.3.5 Merck Recent Development
7.4 Bristol-Myers Squibb
7.4.1 Bristol-Myers Squibb Company Details
7.4.2 Company Description and Business Overview
7.4.3 Cutaneous Fibrosis Treatment Introduction
7.4.4 Bristol-Myers Squibb Revenue in Cutaneous Fibrosis Treatment Business (2014-2019)
7.4.5 Bristol-Myers Squibb Recent Development
7.5 Sanofi
7.5.1 Sanofi Company Details
7.5.2 Company Description and Business Overview
7.5.3 Cutaneous Fibrosis Treatment Introduction
7.5.4 Sanofi Revenue in Cutaneous Fibrosis Treatment Business (2014-2019)
7.5.5 Sanofi Recent Development
7.6 Boehringer Ingelheim
7.6.1 Boehringer Ingelheim Company Details
7.6.2 Company Description and Business Overview
7.6.3 Cutaneous Fibrosis Treatment Introduction
7.6.4 Boehringer Ingelheim Revenue in Cutaneous Fibrosis Treatment Business (2014-2019)
7.6.5 Boehringer Ingelheim Recent Development
7.7 Roche
7.7.1 Roche Company Details
7.7.2 Company Description and Business Overview
7.7.3 Cutaneous Fibrosis Treatment Introduction
7.7.4 Roche Revenue in Cutaneous Fibrosis Treatment Business (2014-2019)
7.7.5 Roche Recent Development
7.8 GlaxoSmithKline
7.8.1 GlaxoSmithKline Company Details
7.8.2 Company Description and Business Overview
7.8.3 Cutaneous Fibrosis Treatment Introduction
7.8.4 GlaxoSmithKline Revenue in Cutaneous Fibrosis Treatment Business (2014-2019)
7.8.5 GlaxoSmithKline Recent Development
7.9 Pfizer
7.9.1 Pfizer Company Details
7.9.2 Company Description and Business Overview
7.9.3 Cutaneous Fibrosis Treatment Introduction
7.9.4 Pfizer Revenue in Cutaneous Fibrosis Treatment Business (2014-2019)
7.9.5 Pfizer Recent Development
7.10 Novartis
7.10.1 Novartis Company Details
7.10.2 Company Description and Business Overview
7.10.3 Cutaneous Fibrosis Treatment Introduction
7.10.4 Novartis Revenue in Cutaneous Fibrosis Treatment Business (2014-2019)
7.10.5 Novartis Recent Development
7.11 LEO Pharma
7.12 Actelion
8 Market Forecast 2019-2025
8.1 Market Size Forecast by Product (2019-2025)
8.2 Market Size Forecast by Application (2019-2025)
8.3 Market Size Forecast by Regions
8.4 North America
8.5 Europe
9 Analyst’s Viewpoints/Conclusions
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Disclaimer
10.3 Author Details
Table Cutaneous Fibrosis Treatment Key Market Segments
Table Key Players Cutaneous Fibrosis Treatment Covered
Table Global Cutaneous Fibrosis Treatment Market Size Growth Rate by Type 2018-2025 (Million US$)
Figuer Immunotherapy Figures
Table Key Players of Immunotherapy
Figuer Corticosteroids Figures
Table Key Players of Corticosteroids
Figuer Anti-Fibrotic Drugs Figures
Table Key Players of Anti-Fibrotic Drugs
Figuer Immunoglobulins Figures
Table Key Players of Immunoglobulins
Table Global Cutaneous Fibrosis Treatment Market Size Growth by Application 2019-2025 (Million US$)
Figure Global Cutaneous Fibrosis Treatment Market Share by Application in 2018 & 2025
Figure Hospitals Pharmacies Case Studies
Figure Retail Pharmacies Case Studies
Figure Online Pharmacies Case Studies
Figure Cutaneous Fibrosis Treatment Report Years Considered
Figure Global Cutaneous Fibrosis Treatment Market Size and Growth Rate 2014-2025 (Million US$)
Table Global Cutaneous Fibrosis Treatment Market Size by Regions 2019-2025 (Million US$)
Table Global Cutaneous Fibrosis Treatment Market Size by Regions 2019-2025 (Million US$)
Table Global Cutaneous Fibrosis Treatment Market Share by Regions 2014-2019
Figure Global Cutaneous Fibrosis Treatment Market Share by Regions 2014-2019
Figure Global Cutaneous Fibrosis Treatment Market Share by Regions in 2018
Table Market Top Trends
Table Key Drivers: Impact Analysis (2019-2025)
Table Key Challenges
Figure PORTER'S FIVE FORCES ANALYSIS
Table Global Cutaneous Fibrosis Treatment Revenue by by Players (2014-2019) (Million US$)
Table Global Cutaneous Fibrosis Treatment Market Share by by Players (2014-2019)
Figure Global Cutaneous Fibrosis Treatment Market Share by by Players in 2018
Table Global Cutaneous Fibrosis Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Cutaneous Fibrosis Treatment Product/Solution/Service
Table Date of Enter into Cutaneous Fibrosis Treatment Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Cutaneous Fibrosis Treatment Market Size by Type (2014-2019) (Million US$)
Table Global Cutaneous Fibrosis Treatment Market Size Share by Type (2014-2019)
Figure Global Cutaneous Fibrosis Treatment Market Size Market Share by Type (2014-2019)
Table Global Cutaneous Fibrosis Treatment Market Size by Application (2014-2019) (Million US$)
Table Global Cutaneous Fibrosis Treatment Market Size Share by Application (2014-2019)
Figure Global Cutaneous Fibrosis Treatment Market Size Market Share by Application (2014-2019)
Figure Global Cutaneous Fibrosis Treatment Revenue Market Share by Application in 2018
Figure North America Cutaneous Fibrosis Treatment Market Size 2014-2019 (Million US$)
Table North America Key Players Cutaneous Fibrosis Treatment Revenue (2018-2019) (Million US$)
Table North America Key Players Cutaneous Fibrosis Treatment Market Share (2018-2019)
Table North America Cutaneous Fibrosis Treatment Market Size by Type 2014-2019 (Million US$)
Table North America Cutaneous Fibrosis Treatment Market Share by Type 2014-2019
Table North America Cutaneous Fibrosis Treatment Market Size by Application 2014-2019 (Million US$)
Table North America Cutaneous Fibrosis Treatment Market Share by Application 2014-2019
Figure Europe Cutaneous Fibrosis Treatment Market Size 2014-2019 (Million US$)
Table Europe Key Players Cutaneous Fibrosis Treatment Revenue (2018-2019) (Million US$)
Table Europe Key Players Cutaneous Fibrosis Treatment Market Share (2018-2019)
Table Europe Cutaneous Fibrosis Treatment Market Size by Type 2014-2019 (Million US$)
Table Europe Cutaneous Fibrosis Treatment Market Share by Type 2014-2019
Table Europe Cutaneous Fibrosis Treatment Market Size by Application 2014-2019 (Million US$)
Table Europe Cutaneous Fibrosis Treatment Market Share by Application 2014-2019
Table AbbVie Company Details
Table AbbVie Revenue in Cutaneous Fibrosis Treatment Business 2014-2019 (Million US$)
Figure AbbVie Revenue Growth Rate in Cutaneous Fibrosis Treatment Business (2014-2019)
Table AbbVie Recent Development
Table Bayer Company Details
Table Bayer Revenue in Cutaneous Fibrosis Treatment Business 2014-2019 (Million US$)
Figure Bayer Revenue Growth Rate in Cutaneous Fibrosis Treatment Business (2014-2019)
Table Bayer Recent Development
Table Merck Company Details
Table Merck Revenue in Cutaneous Fibrosis Treatment Business 2014-2019 (Million US$)
Figure Merck Revenue Growth Rate in Cutaneous Fibrosis Treatment Business (2014-2019)
Table Merck Recent Development
Table Bristol-Myers Squibb Company Details
Table Bristol-Myers Squibb Revenue in Cutaneous Fibrosis Treatment Business 2014-2019 (Million US$)
Figure Bristol-Myers Squibb Revenue Growth Rate in Cutaneous Fibrosis Treatment Business (2014-2019)
Table Bristol-Myers Squibb Recent Development
Table Sanofi Company Details
Table Sanofi Revenue in Cutaneous Fibrosis Treatment Business 2014-2019 (Million US$)
Figure Sanofi Revenue Growth Rate in Cutaneous Fibrosis Treatment Business (2014-2019)
Table Sanofi Recent Development
Table Boehringer Ingelheim Company Details
Table Boehringer Ingelheim Revenue in Cutaneous Fibrosis Treatment Business 2014-2019 (Million US$)
Figure Boehringer Ingelheim Revenue Growth Rate in Cutaneous Fibrosis Treatment Business (2014-2019)
Table Boehringer Ingelheim Recent Development
Table Roche Company Details
Table Roche Revenue in Cutaneous Fibrosis Treatment Business 2014-2019 (Million US$)
Figure Roche Revenue Growth Rate in Cutaneous Fibrosis Treatment Business (2014-2019)
Table Roche Recent Development
Table GlaxoSmithKline Company Details
Table GlaxoSmithKline Revenue in Cutaneous Fibrosis Treatment Business 2014-2019 (Million US$)
Figure GlaxoSmithKline Revenue Growth Rate in Cutaneous Fibrosis Treatment Business (2014-2019)
Table GlaxoSmithKline Recent Development
Table Pfizer Company Details
Table Pfizer Revenue in Cutaneous Fibrosis Treatment Business 2014-2019 (Million US$)
Figure Pfizer Revenue Growth Rate in Cutaneous Fibrosis Treatment Business (2014-2019)
Table Pfizer Recent Development
Table Novartis Company Details
Table Novartis Revenue in Cutaneous Fibrosis Treatment Business 2014-2019 (Million US$)
Figure Novartis Revenue Growth Rate in Cutaneous Fibrosis Treatment Business (2014-2019)
Table Novartis Recent Development
Table LEO Pharma Company Details
Table Actelion Company Details
Table Global Cutaneous Fibrosis Treatment Market Size by Regions (Million US$) 2019-2025
Figure Global Cutaneous Fibrosis Treatment Market Size Share by Regions (2019-2025)
Figure Global Cutaneous Fibrosis Treatment Market Size Share by Regions in 2025
Figure North America Cutaneous Fibrosis Treatment Market Size Forecast (2019-2025)(Million USD)
Figure Europe Cutaneous Fibrosis Treatment Market Size Forecast (2019-2025)(Million USD)
Table Global Cutaneous Fibrosis Treatment Market Size by Product (2019-2025) (Million US$)
Figure Global Cutaneous Fibrosis Treatment Market Size by Product (2019-2025)
Figure Global Cutaneous Fibrosis Treatment Market Size by Product in 2025
Table Global Cutaneous Fibrosis Treatment Market Size by Application (2019-2025) (Million US$)
Figure Global Cutaneous Fibrosis Treatment Market Size by Application (2019-2025)
Figure Global Cutaneous Fibrosis Treatment Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
皮膚肥満細胞症の治療の世界市場：市場規模・現状・予測 Cutaneous mastocytosis is a form of mastocytosis that primarily affects the skin. There are three main forms of the condition: maculopapular cutaneous mastocytosis (also called urticaria pigmentosa), solitary cutaneous mastocytoma, and diffuse cutaneous mastocytosis.In 2018, the global Cutaneous Mas…- 世界の皮膚リーシュマニア症薬市場：動向・競争分析 Cutaneous leishmaniasis is the most common syndrome and can produce ulcers that have the potential of stimulating a periosteal reaction if the ulcer occurs near bone.In 2018, the global Cutaneous Leishmaniasis Drugs market size was xx million US$ and is forecast to xx million US in 2025, growing at …
- 腎線維症治療の世界市場：市場規模・現状・予測 Kidney or renal fibrosis is the body process from which the kidney’s excess fibrous connective tissue or organs takes its formation repetitively.Increasing prevalence of chronic diseases such as kidney disorders is expected to trigger the growth of this market over the forecast period. Changing life…
- 孤立性肺疾患治療の世界市場：市場規模・現状・予測 Orphan illnesses are those which are not generally looked into, those where particular medicines are not accessible, and those which may just be of restricted enthusiasm to researchers and specialists.Orphan lung diseases are exemplified by the purported disregarded infectious diseases, which are en…
- ドライアイ薬およびデバイス治療の世界市場：市場規模・現状・予測 Dry eye disease is a condition that affects the tear film and ocular surface. It is medically known as keratoconjunctivitis sicca. It is an ocular disorder caused by the lack of tear fluid to lubricate the eyes. There are primarily two types of dry eye conditions. One is aqueous tear-deficient dry e…